Agomelatine in the treatment of anhedonia, somatic symptoms, and sexual dysfunction in major depressive disorder

被引:3
|
作者
Huang, Juan [1 ,2 ,3 ]
Xie, Xiao-Meng [1 ,2 ,3 ]
Lyu, Nan [1 ,2 ,3 ]
Fu, Bing-Bing [1 ,2 ,3 ]
Zhao, Qian [1 ,2 ,3 ]
Zhang, Ling [1 ,2 ,3 ]
Wang, Gang [1 ,2 ,3 ]
机构
[1] Capital Med Univ, Beijing Anding Hosp, Natl Clin Res Ctr Mental Disorders, Beijing Key Lab Mental Disorders, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Anding Hosp, Natl Ctr Mental Disorders, Beijing, Peoples R China
[3] Capital Med Univ, Adv Innovat Ctr Human Brain Protect, Beijing, Peoples R China
来源
FRONTIERS IN PSYCHIATRY | 2023年 / 14卷
关键词
major depressive disorder; agomelatine; sexual dysfunction; anhedonia; somatic symptoms; QUALITY-OF-LIFE; STAR-ASTERISK-D; DOUBLE-BLIND; ANTIDEPRESSANT EFFICACY; REUPTAKE INHIBITORS; CHINESE VERSION; ANXIETY; RELIABILITY; FLUOXETINE; METAANALYSIS;
D O I
10.3389/fpsyt.2023.1115008
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
ObjectiveThis study evaluated the treatment outcomes of agomelatine on anhedonic state, anxiety/somatic symptoms, and sexual function in Chinese patients with major depressive disorder (MDD). MethodIn total, 93 adult patients with MDD were enrolled, and 68 of them were included in a prospective, open-label, multicenter clinical study. All patients received agomelatine monotherapy during a 9-week treatment phase. The effectiveness of the treatment was reflected by the improvement of anhedonia and somatic symptoms based on the 17-item Hamilton Depression Rating Scale (HAMD-17). In addition, the Arizona Sexual Dysfunction Scale (ASEX), Sheehan Disability Scale (SDS), and Short Form of Quality-of-Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) were administered to all participants at baseline and at the 3-, 6-, and 9-week follow-ups. ResultsAfter 9 weeks of treatment with agomelatine, the response and remission rates were 73.5% and 39.7%, respectively. Somatic symptoms significantly improved at week 9 (p < 0.001), and significant effects were also observed on the HAMD anhedonia items (p < 0.001). The patients exhibited lower levels of disease severity (the SDS score dropped from 15.52 +/- 4.7 to 7.09 +/- 5.62 at week 9; the ASEX score dropped from 21.89 +/- 4.06 to 16.19 +/- 4.79, p < 0.001) and higher levels of QOL (the Q-LES-Q-SF score dropped from 41.02 +/- 5.99 to 50.49 +/- 8.57, p < 0.001) during the follow-up. Furthermore, treatment with agomelatine improved depressive symptoms without causing serious adverse events. ConclusionThese analyses indicate that agomelatine is a treatment option for improving anhedonic status, anxiety/somatic symptoms, and sexual dysfunction in MDD patients.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] The neural correlates of anhedonia in major depressive disorder
    Keedwell, PA
    Andrew, C
    Williams, SCR
    Brammer, MJ
    Phillips, ML
    BIOLOGICAL PSYCHIATRY, 2005, 58 (11) : 843 - 853
  • [32] ANHEDONIA AND BLUNTED AFFECT IN MAJOR DEPRESSIVE DISORDER
    LOAS, G
    SALINAS, E
    PIERSON, A
    GUELFI, JD
    SAMUELLAJEUNESSE, B
    COMPREHENSIVE PSYCHIATRY, 1994, 35 (05) : 366 - 372
  • [33] Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
    Lee, Kyung Ho
    Han, Tae Sun
    Han, Changsu
    Bahk, Won-Myong
    Lee, Soo-Jung
    Patkar, Ashwin A.
    Masand, Prakash S.
    Pae, Chi-Un
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2023, 21 (03) : 594 - 598
  • [34] Sexual dysfunction and quality of life in women with major depressive disorder
    Hopulele-Petri, A.
    Fadgyas-Stanculete, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S416 - S416
  • [35] Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder
    Papakostas, GI
    Petersen, T
    Hughes, ME
    Nierenberg, AA
    Alpert, JE
    Fava, M
    PSYCHIATRY RESEARCH, 2004, 126 (03) : 287 - 290
  • [36] Agomelatine Treatment of Major Depressive Disorder in Parkinson's Disease: A Case Series
    De Berardis, Domenico
    Fornaro, Michele
    Serroni, Nicola
    Olivieri, Luigi
    Marini, Stefano
    Moschetta, Francesco Saverio
    Srinivasan, Venkataramanujam
    Assetta, Maurizio
    Valchera, Alessandro
    Salone, Anatolia
    Martinotti, Giovanni
    Onofrj, Marco
    Di Giannantonio, Massimo
    JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2013, 25 (04) : 343 - 345
  • [37] Typical somatic symptoms of pregnancy and their impact on a diagnosis of major depressive disorder
    Yonkers, Kimberly Ann
    Smith, Megan V.
    Gotman, Nathan
    Belanger, Kathleen
    GENERAL HOSPITAL PSYCHIATRY, 2009, 31 (04) : 327 - 333
  • [38] Migraine: A missing link between somatic symptoms and major depressive disorder
    Hung, Ching-I
    Liu, Chia-Yih
    Cheng, Yu-Ting
    Wang, Shuu-Jiun
    JOURNAL OF AFFECTIVE DISORDERS, 2009, 117 (1-2) : 108 - 115
  • [39] Gender differences in major depressive disorder: somatic symptoms and quality of life
    Saiz Gonzalez, Dolores
    Rodriguez, Mercedes
    Garcia, Carmen
    Prieto, Rita
    Saiz-Ruiz, Jeronimo
    REVISTA DE PSIQUIATRIA Y SALUD MENTAL, 2009, 2 (03): : 119 - 127
  • [40] ECONOMIC EVALUATION OF AGOMELATINE FOR MAJOR DEPRESSIVE DISORDER IN SWEDEN
    Clapham, E.
    Berg, J.
    Ekman, M.
    Jonsson, L.
    VALUE IN HEALTH, 2009, 12 (03) : A176 - A176